...
首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Sickle cell disease: Its molecular mechanism and the one drug that treats it
【24h】

Sickle cell disease: Its molecular mechanism and the one drug that treats it

机译:镰状细胞病:其分子机制和治疗它的一种药物

获取原文
获取原文并翻译 | 示例
           

摘要

Sickle cell disease is probably the first known assembly disease, and its mechanism has been extensively studied. It arises because of the expression of a mutant hemoglobin that can polymerize, and which does so by a double nucleation mechanism that is now seen to operate in other diseases. The polymers so formed lead to circulatory obstruction in the microcirculation. The accuracy of the description that has been developed is sufficient to describe precisely the impact of molecules that cannot join polymers but that still crowd the solution, including fetal hemoglobin. The one approved drug, hydroxyurea, is thought to achieve its benefit by enhancing the production of fetal hemoglobin, but the effects of the drug on polymerization exceed what the added fetal hemoglobin can accomplish. While some possible answers to this mystery are suggested, no mechanism has been conclusively established for the remarkably efficacy of the one drug available to treat this disease. (C) 2016 Elsevier B.V. All rights reserved.
机译:镰状细胞病可能是第一个已知的装配性疾病,其机理已得到广泛研究。它的产生是由于可以聚合的突变型血红蛋白的表达,而这种突变是通过双重成核机制实现的,该机制目前在其他疾病中也起作用。如此形成的聚合物导致微循环中的循环阻塞。已经发展的描述的准确性足以精确描述不能加入聚合物但仍然拥挤溶液的分子的影响,包括胎儿血红蛋白。人们认为一种批准的药物羟基脲可通过增加胎儿血红蛋白的产生来实现其益处,但该药物对聚合的作用超过了添加的胎儿血红蛋白所能达到的效果。虽然提出了对该谜题的一些可能答案,但尚未就可用于治疗该疾病的一种药物的显着疗效建立结论性的机制。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号